John Libbey Eurotext

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement

MENU

Amylose cardiaque dite sénile : diagnostic et nouvelles perspectives thérapeutiques Volume 20, issue 1, Mars 2022

Figures

Tables



Authors
1 Nantes Université, CHU Nantes, Pôle hospitalo-universitaire de Gérontologie Clinique, Nantes, France
2 Nantes Université, CHU Nantes, CNRS, Inserm, Institut du thorax, Nantes, France
3 Université de Paris, EA4468, Service de gériatrie, AP-HP, Hôpitaux Universitaires Paris Centre, Hôpital Broca, Paris, France
* Correspondance : G. Berrut

So-called senile cardiac amyloidosis was considered rare. Nowadays, thanks to non-invasive diagnostic means and autopsy studies, we estimate the prevalence to be about 20% of subjects over 75 years of age. Similarly, amyloidosis was a diagnosis with no therapeutic consequences, apart from the treatment of heart failure and conduction disorders. New treatments make it possible to stabilise the transthyretin tetramer and to reduce the production of oligomers that are the source of amyloid deposits, by acting in a non-genetic way and therefore adapted to the “wild” transthyretin forms of so-called senile cardiac amyloidosis. Thus, the diagnosis and management of cardiac amyloidosis are becoming diagnostic procedures in clinical practice and must be known by cardiologists, but also by geriatricians, who will allow early and therefore more effective management.